Sequential Combination Chemotherapy (Caboppivim) for the Treatment of High-Grade Malignant Non-Hodgkin Lymphoma

References

• Armitage J O, Fyfe M AE, Lewis J. Long term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 1984; 2: 898–902
   PubMed Web of Science ®Google Scholar
• Canellos G P, Skarin A T, Klatt M M, et al. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol 1987; 24: 2–7, Suppl 1
   PubMed Web of Science ®Google Scholar
• Fisher R I, Young R C, Longo D, et al. Pro-MACE-MOPP combination chemotherapy for diffuse lymphomas. Semin Oncol 1985; 12: 29–32, Suppl 2
   PubMed Web of Science ®Google Scholar
• Gaynor E R, Ultmann J E, Golomb H M, et al. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclo-phosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): A 10-year experience in a single institution. J Clin Oncol 1985; 12: 1596–1604
   Google Scholar
• Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Laurence J, Coleman M, Allen S L, et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med 1982; 97: 190–5
   PubMed Web of Science ®Google Scholar
• Skarin AT. Diffuse aggressive lymphomas: A curable subset of non-Hodgkin's lymphomas. Semin Oncol 1986; 13: 10–25, Suppl 5
   PubMedGoogle Scholar
• Coleman M, Gerstein G, Topilow A, et al. Advances in chemotherapy for large cell lymphoma. Semin Hematol 1987; 24: 8–20, Suppl 1
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors JM. Updated clinical experience with MACOP-B. Semin Hernatol 1987; 24: 26–34, Suppl 1
   PubMed Web of Science ®Google Scholar
• Fisher R I, Miller T P, Dana B W, et al. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol 1987; 24: 21–5, Suppl 2
   PubMed Web of Science ®Google Scholar
• Froimtchuk M, Olivatto L O, Gil R A, et al. MACOP-B: Effective treatment for malignant lymphomas. Proc ECCO-4, Madrid 1987; 260
   Google Scholar
• Lowenthal D A, White A, Koziner B, et al. MACOP-B for advanced diffuse intermediate and high-grade non-Hodgkin's lymphoma (NHL): Preliminary results of the Memorial Hospital experience. Proc ASCO 1987; 6: 201
   Google Scholar
• Oliverio V T, Denham C, DeVita V T, et al. Some pharmacologic properties of a new antitumor agent, N-isopropyl-a-(2-methylhydrazino)-p-toluamide, hydrochloride (NSC-77213). Cancer Chemother Rep 1964; 42: 1–7
   PubMedGoogle Scholar
• Spivak SD. Procarbazine. Ann Intern Med 1974; 81: 795–800
   Google Scholar
• Cabanillas F, Hagemeister F, Bodey G P, et al. Ifosfamide, methotrexare, VP-16 (IMVP-16), an effective salvage regimen for lymphoma. Blood 1982; 60: 693–7
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Burgess M A, Bodey G P, et al. Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. Am J Med 1983; 74: 382–8
   PubMed Web of Science ®Google Scholar
• Cabanillas F. Ifosfamide combinations in the management of lymphomas. Karger, Contr Oncol, Basel 1987; 26: 394–9
   Google Scholar
• Nowrousian M R, Schoetensack B, Pfeiffer R, et al. Combination chemotherapy with etoposide (VP-16), ifosfamide, methotrexate, and bleomycin (VIM(B)) for refractory or recurrent lymphomas. Contr Oncol 1987; 26: 414–22
   Google Scholar
• Hall S W, Strong J E, Broughton A, et al. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 1982; 9: 22–25
   PubMed Web of Science ®Google Scholar
• Ginsberg S J, Crooke S T, Bloomfield C D, et al. Cyclophos-phamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study No. 7804. Cancer 1982; 49: 1346–52
   PubMed Web of Science ®Google Scholar
• Hollister D, Silver R T, Gordon B, et al. Continuous infusion vincristine and bleomycin with high-dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer 1982; 50: 1690–4
   PubMed Web of Science ®Google Scholar
• Krakoff I H, Cvitkovic E, Cunie V, et al. Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer 1977; 40: 2027–37
   PubMed Web of Science ®Google Scholar
• Sikic B I, Collins J M, Mimnaugh E G, et al. Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 1978; 62: 2011–7
   PubMedGoogle Scholar
• Armitage J O, Dick F R, Corder M P, et al. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, Adriamycin, vincristin and prednisone (CHOP). Cancer 1982; 50: 1695–1702
   PubMed Web of Science ®Google Scholar
• DeVita VT, Jr, Canellos G P, Chabner B, et al. Advanced diffuse histocytic lymphoma, a potentially curable disease: Results in combination therapy. Lancet 1975; 1: 248–50
   PubMed Web of Science ®Google Scholar
• McKelvey E M, Gottlieb J A, Wilson H E, et al. Hydroxyl-daunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–93
   PubMed Web of Science ®Google Scholar
• Skarin A T, Rosenthal D S, Moloney W C, et al. Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, Adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). Blood 1977; 49: 759
   PubMed Web of Science ®Google Scholar
• Fisher R I, DeVita VT, Jr, Hubbard S M, et al. Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med 1983; 98: 304–9
   PubMed Web of Science ®Google Scholar
• Kath R, Schumacher G, Giinzel K, et al. Preliminary results of the MACOP-B regimen in patients with high-grade malignant lymphoma. Blut 1987; 55: 331
   Google Scholar
• Canellos G P, Shipp M S, Hamngton D P, . Prognostic factors in diffuse large cell lymphoma. Update on treatment for diffuse large cell lymphoma, A T Skarin, et al. Park Row, New York 1986; 11–5
   Google Scholar
• Fisher R I, DeVita VT, Jr, Johnson B L, et al. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 1977; 63: 177–82
   PubMed Web of Science ®Google Scholar
• Fisher R I, Hubbard S M, DeVita V T, et al. Factors predicting long-term survival in diffuse mixed, histiocytic, or undiffer-entiated lymphoma. Blood 1981; 58: 45–51
   PubMed Web of Science ®Google Scholar
• Jagannath S, Velasquez W S, Tucker S L, et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large cell lymphoma. J Clin Oncol 1986; 4: 859–65
   PubMed Web of Science ®Google Scholar
• Shipp M A, Hanington D P, Klatt M M, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104: 757–65
   PubMed Web of Science ®Google Scholar